Admission to trading on the London Stock Exchange

RNS Number : 5148C

Circassia Pharmaceuticals Plc

18 March 2014

 



NOT INTENDED TO PROMOTE THE SALE OF ANY SECURITIES, AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT OR ANY COPY OF IT

FOR IMMEDIATE RELEASE

18 March 2014

Circassia Pharmaceuticals plc

Admission to trading on the London Stock Exchange

Further to its announcements on 13 March 2014 relating to its initial public offering (the "Offer"), Circassia Pharmaceuticals plc ("Circassia" or the "Company"), a clinical-stage specialty biopharmaceutical company, is pleased to announce that its entire issued ordinary share capital of 187,422,379 ordinary shares (the "Shares") has today been admitted to the premium listing segment of the Official List of the UK Listing Authority and to trading on the London Stock Exchange's main market for listed securities under the ticker "CIR.".

Notes to editors:

Circassia is a specialty biopharmaceutical company focused on the development and commercialisation of a range of immunotherapy products for the treatment of allergy. Established in 2006, the Company has used its innovative proprietary technology, ToleroMune® to develop a new class of allergy therapies, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs), which Circassia believes represents a step change to a new generation of allergy treatment. The Company's portfolio of product candidates is designed to treat a broad range of seasonal and perennial allergies. The lead product candidate Cat-SPIRE, a new treatment for cat allergy, is currently in phase III development and three other product candidates have completed phase IIb development. As Circassia continues to grow, the Company remains focused on its founding principle - a commitment to improving patients' lives by controlling immune responses. Further information is available at: www.circassia.co.uk.

Enquiries:

For further information please contact:

Circassia	[phone]
Steven Harris, Chief Executive Officer
Julien Cotta, Chief Financial Officer
Lara Flynn, Vice President of Corporate Affairs
Public Relations Adviser to Circassia
FTI Consulting	[phone]
Ben Atwell
John Dineen
Global Co-ordinator, Sole Sponsor and Joint Bookrunner
J.P. Morgan Cazenove	[phone]
Nicholas Hall
Gina Gibson
Joint Bookrunner
Peel Hunt	[phone]
Jock Maxwell Macdonald
James Steel
Co-Manager
Canaccord Genuity	[phone]
Lucy Tilley
Julian Feneley
Co-Manager
Shore Capital	[phone]
Bidhi Bhoma
Edward Mansfield

Important notice

This announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any Shares or any other securities, nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, or act as an inducement to enter into, any contract therefor.

Neither this announcement nor any copy of it may be made or transmitted into the United States, or distributed, directly or indirectly, in the United States. Neither this announcement nor any copy of it may be taken or transmitted directly or indirectly into Australia, Canada or Japan or to any persons in any of those jurisdictions, except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of United States, Australian, Canadian or Japanese securities laws. The distribution of this announcement in other jurisdictions may be restricted by law and persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions. This announcement is not an offer of securities for sale, or a solicitation of an offer to purchase securities in the United States, Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful.

The securities to which this announcement relates have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or with any regulating authority or under any applicable securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States unless registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable state law. There will be no public offer of the securities in the United States.

The securities referred to herein have not been registered under the applicable securities laws of Australia, Canada or Japan and, subject to certain exceptions, may not be offered or sold within Australia, Canada or Japan or to any national, resident or citizen of Australia, Canada or Japan.

In any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") other than the United Kingdom, this announcement is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.

J.P. Morgan Cazenove, which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the FCA and the PRA in the United Kingdom, and Peel Hunt, Canaccord Genuity and Shore Capital, each of which is authorised and regulated by the FCA in the United Kingdom, are acting exclusively for Circassia and no-one else in connection with the Offer, will not regard any other person as their respective client in relation to the Offer, and will not be responsible to anyone other than Circassia for providing the protections afforded to their respective clients, nor for providing advice in relation to the Offer, advice in relation to Admission, the contents of this announcement or any transaction, arrangement or other matter referred to herein.

 

END

 

 

MSCEANDXFFLLEFF